These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 26725724)

  • 1. Insight into the Development of Dissolution Media for BCS Class II Drugs: A Review from Quality Control and Prediction of In Vivo Performance Perspectives.
    Wu C; Liu Y; He Z; Sun J
    Curr Drug Deliv; 2016; 13(7):1004-1020. PubMed ID: 26725724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.
    Takano R; Sugano K; Higashida A; Hayashi Y; Machida M; Aso Y; Yamashita S
    Pharm Res; 2006 Jun; 23(6):1144-56. PubMed ID: 16715363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is the full potential of the biopharmaceutics classification system reached?
    Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
    Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
    Buckley ST; Frank KJ; Fricker G; Brandl M
    Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissolution behavior of various drugs in different FaSSIF versions.
    Klumpp L; Leigh M; Dressman J
    Eur J Pharm Sci; 2020 Jan; 142():105138. PubMed ID: 31704344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs.
    Galia E; Nicolaides E; Hörter D; Löbenberg R; Reppas C; Dressman JB
    Pharm Res; 1998 May; 15(5):698-705. PubMed ID: 9619777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of GIS and Biphasic to Better Predict In Vivo Dissolution of BCS Class IIb Drugs, Ketoconazole and Raloxifene.
    Tsume Y; Igawa N; Drelich AJ; Amidon GE; Amidon GL
    J Pharm Sci; 2018 Jan; 107(1):307-316. PubMed ID: 28919384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
    Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies.
    Kleberg K; Jacobsen J; Müllertz A
    J Pharm Pharmacol; 2010 Nov; 62(11):1656-68. PubMed ID: 21039549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical profiling (solubility, permeability and charge state).
    Avdeef A
    Curr Top Med Chem; 2001 Sep; 1(4):277-351. PubMed ID: 11899112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review.
    Kumar S; Bhargava D; Thakkar A; Arora S
    Crit Rev Ther Drug Carrier Syst; 2013; 30(3):217-56. PubMed ID: 23614647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of In Vivo Predictive Dissolution Media Using Drug Substance and Physiological Properties.
    Mudie DM; Samiei N; Marshall DJ; Amidon GE; Bergström CAS
    AAPS J; 2020 Jan; 22(2):34. PubMed ID: 31989343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biopharmaceutical considerations of dissolution testing used as a prognostic tool for oral drug adsorption].
    Antal I
    Acta Pharm Hung; 2001 Oct; 71(3):280-8. PubMed ID: 11961894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.
    Lehto P; Kortejärvi H; Liimatainen A; Ojala K; Kangas H; Hirvonen J; Tanninen VP; Peltonen L
    Eur J Pharm Biopharm; 2011 Aug; 78(3):531-8. PubMed ID: 21329757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The dissolution test in biorelevant media as a prognostic tool for modeling of drug behavior in vivo].
    Ramenskaia GV; Shokhin IE; Savchenko AIu; Volkova EA
    Biomed Khim; 2011; 57(5):482-9. PubMed ID: 22629598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
    Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
    AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro models for the prediction of in vivo performance of oral dosage forms.
    Kostewicz ES; Abrahamsson B; Brewster M; Brouwers J; Butler J; Carlert S; Dickinson PA; Dressman J; Holm R; Klein S; Mann J; McAllister M; Minekus M; Muenster U; Müllertz A; Verwei M; Vertzoni M; Weitschies W; Augustijns P
    Eur J Pharm Sci; 2014 Jun; 57():342-66. PubMed ID: 23988843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.